Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   

Out of the shadows - Living with dementia

adam101 - age-related cognitive disorders1 - cognition2 - saykin1 - amyloid β1 - structural imaging1 - apoe-e4 gene1 - against alzheimer's disease1 - slowed movement1 - moderate intensity aerobic exercise1 - neuropsychological tests1 - creutzfeldt-jakob disease5 - alzheimer's drugs4 - signs of parkinson's1 - gradual degeneration1 - fischer1 - aβ421 - novel proteins1 - hyperammonemia1 - dementia135 - korsakoff's psychosis5 - initiative1 - reversible dementia1 - visuospatial deficits1 - neurofibrillary tangles3 - anxiety1 - alzheimers society2 - mildcognitive impairment1 - frontotemporal dementia signs1 - sleep disturbances1 -